Advancing the systemic therapy of lung cancer: quality or quantity?

Affiliations

¹ Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, ON M5G 1Z5, Canada.
² Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, ON M5G 1Z5, Canada. Electronic address: natasha.leighl@uhn.ca.

Comment

Andrea S Fung et al. Lancet Oncol. 2020 Mar.

. 2020 Mar;21(3):322-324.

doi: 10.1016/S1470-2045(20)30076-0. Epub 2020 Feb 6.

¹ Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, ON M5G 1Z5, Canada.
² Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, ON M5G 1Z5, Canada. Electronic address: natasha.leighl@uhn.ca.

No abstract available

Comment on

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D. Garassino MC, et al. Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6. Lancet Oncol. 2020. PMID: 32035514 Clinical Trial.